Blueprint Medicines
Focus: Blueprint Medicines is a public-stage biotechnology company headquartered in Cambridge, MA, specializing in small-molecule discovery across oncology, women's health, and dermatology. The company has achieved commercial scale with marketed products generating meaningful revenue.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
1
Should You Work at Blueprint Medicines?
AI assessmentBlueprint offers stability through a peak-revenue product with extended patent life, but career growth depends on pipeline maturation and willingness to operate in a concentrated, small-molecule oncology environment.
Why Work Here
- AYVAKIT (avapritinib) is at peak lifecycle with patent protection extending to 2042, providing revenue stability and long-term career continuity
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$55M Part DStable
Peak
Help build intelligence for Blueprint Medicines
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.